A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

CLINICALTRIALS.GOV IDENTIFIER	RECRUITMENT STATUS	FIRST POSTED	LAST UPDATE POSTED
NCT05328908	RECRUITING	APRIL 14, 2022	JULY 29, 2022

STUDY DESCRIPTION

Brief Summary

The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of late-line microsatellite stable (MSS) metastatic colorectal cancer (mCRC) participants who failed at least 1 but no more than 4 prior lines of therapy for metastatic disease.

Condition or Disease: Colorectal Neoplasms

Intervention/treatment: Drug: Nivolumab-relatlimab FDC
Drug: Regorafenib
Drug: TAS-102

Phase: Phase 3

DETAILED DESCRIPTION

N/A

STUDY DESIGN

Study Type: Interventional

Estimated Enrollment : 700 participants

Allocation : Randomized

Intervention Model : Parallel Assignment

Masking: None (Open Label) ()

Primary Purpose: Treatment

Official Title: A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

Actual Study Start Date: April 2022

Estimated Primary Completion Date: January 2025

Estimated Study Completion Date: May 2028

ARMS AND INTERVENTIONS

Arm	Intervention/treatment
Experimental: Arm A: Nivolumab + Relatlimab Fixed-dose Combination (FDC)	Drug: Nivolumab-relatlimab FDC Specified dose on specified days
Active Comparator: Arm B: Investigator's Choice Treatment with Regorafenib or TAS-102	Drug: Regorafenib Specified dose on specified days Drug: TAS-102 Specified dose on specified days

OUTCOME MEASURES

Primary Outcome Measures:
1. Overall survival (OS) in randomized participants with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 1 [Time Frame: Up to 5 years after last participant randomized]
2. OS in all randomized participants [Time Frame: Up to 5 years after last participant randomized]

Secondary Outcome Measures:
1. Objective response rate (ORR) by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in randomized participants with PD-L1 CPS ≥ 1 [Time Frame: Up to 5 years after last participant randomized]
2. ORR by BICR per RECIST v1.1 in all randomized participants [Time Frame: Up to 5 years after last participant randomized]
3. Progression-free survival (PFS) by BICR per RECIST v1.1 in randomized participants with PD-L1 CPS ≥ 1 [Time Frame: Up to 5 years after last participant randomized]
4. PFS by BICR per RECIST v1.1 in all randomized participants [Time Frame: Up to 5 years after last participant randomized]
5. Duration of response (DoR) by BICR per RECIST v1.1 in responders with PD-L1 CPS ≥ 1 [Time Frame: Up to 5 years after last participant randomized]
6. DoR by BICR per RECIST v1.1 in all responders [Time Frame: Up to 5 years after last participant randomized]
7. Number of participants with adverse events (AEs) [Time Frame: Up to 135 days after participant's last dose]
8. Number of participants with serious adverse events (SAEs) [Time Frame: Up to 135 days after participant's last dose]
9. Number of participants with immune-mediated adverse events (IMAEs) [Time Frame: Up to 135 days after participant's last dose]
10. Number of participants with AEs leading to discontinuation [Time Frame: Up to 135 day's after participant's last dose]
11. Number of participants with clinical laboratory abnormalities [Time Frame: Up to 135 days after participant's last dose]

12. DeFS-QoL: The time from randomization to death or at least a 15-points worsening from baseline in the EORTC QLQ-C30 GHS/QoL scale, with no subsequent improvement above the 15-point worsening from baseline score [Time Frame: Up to 5 years after last participant randomized]
DeFS-QoL = Deterioration Free Survival-Quality of Life. The EORTC (European Organisation for Research and Treatment of Cancer) Quality of Life Questionnaire-Core 30 (QLQ-C30) consists of 30 questions incorporated into 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 multi-item symptom scales (fatigue, pain, nausea and vomiting), a global health status / Quality of Life scale, and six single symptom items. All of the scale and single-item measures range in score from 0 to 100, where a higher score represents a higher response level. High functional scores indicates more favorable outcomes and a higher score on the symptom domains indicates higher symptom burden/less favorable patient outcome.
13. DeFS-PF: The time from randomization to death or at least a 10-points worsening from baseline in the EORTC QLQ-C30 physical function scale, with no subsequent improvement above the 10-point worsening from baseline score [Time Frame: Up to 5 years after last participant randomized]
DeFS-PF = Deterioration Free Survival-Physical Function. The EORTC (European Organisation for Research and Treatment of Cancer) Quality of Life Questionnaire-Core 30 (QLQ-C30) consists of 30 questions incorporated into 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 multi-item symptom scales (fatigue, pain, nausea and vomiting), a global health status / Quality of Life scale, and six single symptom items. All of the scale and single-item measures range in score from 0 to 100, where a higher score represents a higher response level. High functional scores indicates more favorable outcomes and a higher score on the symptom domains indicates higher symptom burden/less favorable patient outcome.

ELIGIBILITY CRITERIA

Ages Eligible for Study: 18 Years and older (Adult, Older Adult)

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:
Histological confirmed previously treated colorectal cancer with adenocarcinoma histology with metastatic or recurrent unresectable disease at study entry Must have historically or locally confirmed tumor microsatellite stability (stable) (MSS) / proficient mismatch repair (pMMR) status
Participants must have:
progressed during or within approximately 3 months following the last administration of approved standard therapies (at least 1, but not more than 4 prior lines of therapies), which must include a fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF therapy, and anti-EGFR therapy (if KRAS wild-type), if approved in the respective country, or; been intolerant to prior systemic chemotherapy regimens if there is documented evidence of clinically significant intolerance despite adequate supportive measures Must have sufficient tumor tissue & evaluable PD-L1 expression to meet the study requirements Must have measurable disease per RECIST v1.1. Participants with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately
Exclusion Criteria:
Prior treatment with either an immunotherapy or with regorafenib or with TAS-102 Untreated central nervous system (CNS) metastases, participants are eligible if CNS metastases have been treated and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) History of refractory hypertension not controlled with anti-hypertensive therapy, myocarditis (regardless of etiology), uncontrolled arrhythmias, acute coronary syndrome within 6 months prior to dosing, Class II congestive heart failure (as per the New York Heart Association Functional Classification), interstitial lung disease/pneumonitis or an active, known or suspected autoimmune disease
Other protocol-defined inclusion/exclusion criteria apply

CONTACTS AND LOCATIONS

Contacts

Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com 855-907-3286 Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #.

Locations

United States, Arkansas	Local Institution	Rogers
United States, California	City Of Hope	Duarte
United States, California	Local Institution	Los Angeles
United States, Connecticut	Eastern Connecticut Hematology And Oncology Associates	Norwich
United States, Florida	Local Institution	Miami
United States, Georgia	Northside Hospital	Atlanta
United States, Idaho	Local Institution	Boise
United States, Illinois	Local Institution	Chicago
United States, Indiana	Fort Wayne Medical Oncology & Hematology	Fort Wayne
United States, Michigan	Local Institution	Ann Arbor
United States, Minnesota	Mayo Clinic in Arizona - Phoenix	Rochester
United States, New Jersey	Astera Cancer Care	East Brunswick
United States, North Carolina	Local Institution	Durham
United States, Ohio	Local Institution	Cincinnati
United States, Ohio	Local Institution	Columbus

United States, Ohio	Local Institution	Columbus
United States, Pennsylvania	Local Institution	Philadelphia
United States, South Carolina	Charleston Hematology Oncology Associates CHOA	Charleston
United States, South Dakota	Local Institution	Sioux Falls
United States, Texas	The Center For Cancer And Blood Disorders	Fort Worth
United States, Wisconsin	Local Institution	Madison
Argentina, Buenos Aires	Local Institution - 0022	Ciudad Autonoma Buenos Aires
Argentina, Buenos Aires	Local Institution	Ciudad Autónoma Buenos Aires
Argentina, RIO Negro	Local Institution	Viedma
Argentina	Local Institution	Buenos Aires
Argentina	Local Institution	Buenos Aires
Australia, New South Wales	Local Institution	Wagga Wagga
Australia, New South Wales	Local Institution	Westmead
Australia, Queensland	Local Institution - 0001	Greenslopes Qld
Australia, South Australia	Local Institution - 0002	Woodville South
Australia, Victoria	Local Institution - 0010	Clayton
Australia, Victoria	Local Institution	Melbourne
Australia, Western Australia	Local Institution - 0027	Perth
Austria	Local Institution	Graz
Austria	Local Institution	Klagenfurt
Belgium	Local Institution	Edegem
Belgium	Local Institution	Gent
Belgium	Local Institution	Leuven
Belgium	Local Institution	Woluwé-Saint-Lambert
Canada, Alberta	Local Institution	Edmonton
Canada, Ontario	Local Institution	Ottawa
Canada, Ontario	Local Institution	Toronto
Canada, Quebec	Local Institution	Montreal
Canada, Quebec	Local Institution	Montreal
Canada, Quebec	Local Institution	Sherbrooke
Chile, Metropolitana	Local Institution	Santiago
Chile, Metropolitana	Local Institution	Santiago
China, Beijing	Local Institution - 0122	Beijing
China, Hunan	Local Institution - 0125	Changsha
Czechia	Local Institution	Horovice
Czechia	Local Institution	Hradec Kralove
Czechia	Local Institution	Olomouc
Czechia	Local Institution	Prague 5
France	Local Institution	Bordeaux
France	Local Institution	Caen
France	Local Institution	Dijon
France	Local Institution	Levallois-Perret
France	Local Institution	Lyon
France	Local Institution	Paris cedex 12
France	Local Institution	Suresnes

Germany	Local Institution	Berlin
Germany	Local Institution	Essen
Germany	Local Institution	Frankfurt A. Main
Germany	Local Institution	Hamburg
Germany	Local Institution	Mannheim
Germany	Local Institution	Muenchen
Germany	Local Institution	Reutlingen
Germany	Local Institution	Wuerzburg
Italy	Local Institution	Catania
Italy	Local Institution	Genova
Italy	Local Institution	Milano
Italy	Local Institution	Milano
Italy	Local Institution	Napoli
Italy	Local Institution	Napoli
Italy	Local Institution - 0136	Padova
Italy	Local Institution	Reggio Emilia
Japan, Chiba	Local Institution	Chiba-shi
Japan, Chiba	Local Institution	Kashiwa-shi
Japan, Ehime	Local Institution	Matsuyama-shi
Japan, Hokkaido	Local Institution	Sapporo-shi
Japan, Kanagawa	Local Institution	Kawasaki-shi
Japan, Osaka	Local Institution	Suita-shi
Japan, Saitama	Local Institution	Hidaka-Shi
Japan, Saitama	Local Institution	Kitaadachi-gun
Japan, Shizuoka	Local Institution	Sunto-gun
Japan, Tokyo	Local Institution	Chuo-ku
Japan, Tokyo	Local Institution - 0108	Koto-ku
Japan	Local Institution	Osaka
Korea, Republic of	Local Institution	Goyangsi Ilsandonggu
Korea, Republic of	Local Institution	Seoul
Korea, Republic of	Local Institution	Seoul
Korea, Republic of	Local Institution	Seoul
Korea, Republic of	Local Institution	Songpa-gu, Seoul
Netherlands	Local Institution	Amsterdam
Netherlands	Local Institution	Utrecht
Poland	Local Institution	Krakow
Poland	Local Institution	Warszawa
Poland	Local Institution	Warszawa
Poland	Local Institution	Warszawa
Puerto Rico	Local Institution - 0106	San Juan
Singapore	Local Institution	Singapore
Singapore	Local Institution	Singapore
Spain	Local Institution	A Coruña
Spain	Local Institution	Badalona
Spain	Local Institution	Barcelona

Spain	Local Institution	Barcelona
Spain	Local Institution	Madrid
Spain	Local Institution	Madrid
Spain	Local Institution	Sevilla
Spain	Local Institution	Zaragoza
Sweden	Local Institution	Goteborg
Sweden	Local Institution	Malmo
Sweden	Local Institution	Stockholm
Sweden	Local Institution	Uppsala
Switzerland	Local Institution	Aarau
Switzerland	Local Institution	Bern
Taiwan	Local Institution	Kao-Hsiung
Taiwan	Local Institution	Tainan
Taiwan	Local Institution	Tainan

Sponsors and Collaborators

Bristol-Myers Squibb

Investigator

Study Director :	Bristol-Myers Squibb	Bristol-Myers Squibb

MORE INFORMATION

Responsible Party :	Bristol-Myers Squibb
ClinicalTrials.gov Identifier :	NCT05328908
Other Study ID Numbers :	CA224-123, 2021-004285-35
First Posted :	April 14, 2022
Last Update Posted :	July 29, 2022
Last Verified :	July 2022
Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No
Keywords provided by Bristol-Myers Squibb:	*Regorafenib* *Relatlimab* *Nivolumab* *Micro-satellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) BMS-986213* *Stivarga* *Lonsurf*
Additional relevant MeSH terms :	*Intestinal Neoplasms* *Gastrointestinal Neoplasms* *Digestive System Neoplasms* *Neoplasms by Site* *Neoplasms* *Digestive System Diseases* *Gastrointestinal Diseases* *Colonic Diseases* *Intestinal Diseases* *Rectal Diseases* *Colorectal Neoplasms*